CHANGCHUNDAXING<08067> - Results Announcement (Q2, 2004, Summary) Changchun Da Xing Pharmaceutical Company Limited announced on 13/8/2004: (stock code: 08067 ) Year end date :31/12/2004 Currency :RMB Auditors' report :N/A 2nd Quarterly Report Reviewed by Audit Committee Important Note : This result announcement form only contains extracted information from and should be read in conjunction with the detailed results announcement of the issuer, which can be viewed on the GEM website at http://www.hkgem.com (Unaudited) (Unaudited) Current Last Corresponding Period Period from 01/01/2004 from 01/01/2003 to 30/06/2004 to 30/06/2003 $'000 $'000 Turnover : 52,545 35,883 Profit/(Loss) from Operations : 26,112 16,037 Finance cost : (2,010) (603) Share of Profit/(Loss) of Associates : N/A N/A Share of Profit/(Loss) of Jointly Controlled Entites : N/A N/A Profit/(Loss) after Taxation & MI : 24,102 15,464 % Change Over the Last Period : +55.86% EPS / (LPS) Basic (in dollar) : RMB 0.043 RMB 0.028 Diluted (in dollar) : N/A N/A Extraordinary (ETD) Gain/(Loss) : N/A N/A Profit (Loss) after ETD Items : 24,102 15,464 2nd Quarter Dividends per Share : NIL NIL (specify if with other options) : N/A N/A B/C Dates for 2nd Quarter Dividends : N/A Payable Date : N/A B/C Dates for (-) General Meeting : N/A Other Distribution for Current Period : NIL B/C Dates for Other Distribution : N/A (bdi: both days inclusive) For and on behalf of Changchun Da Xing Pharmaceutical Company Limited Signature : Name : Yau Wing Yiu Title : Qualified Accountant Responsibility statement The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this results announcement form (the "Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information are accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make the Information herein inaccurate or misleading.The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information. Remarks: 1. Basis of presentation The Company was incorporated as a joint stock limited company in the People's Republic of China ("PRC") on 27 December 1993 under the provisions of the PRC Company Law. The Company's H shares were listed on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited on 28 June 2002. The Company is principally engaged in the manufacture and sale of medicine in the PRC. On 17 January 2003, the Company set up a new company in the PRC, Changchun Zhong Da Healthcare Product Company Limited with one of its major shareholders, Changchun Kuancheng Pharmaceutircal Factory. The Company is 60% owned by the Company and 40% by Changchun Kuancheng Pharmaceutical Factory. The principal activity of the Company is production of healthcare medication products. The interim financial statements has been prepared in accordance with GEM Listing Rules of the Stock Exchange and the Statements of Standard Accoutning Practice No. 2.125 " Interim Financial Reporting" issued by the Hong Kong Society of Accountants. 2. Principal accounting policies The principal accounting policies adopted in preparing this interim financial statements are the same as that adopted in preparing the annual financial statements for the year ended 31 December 2003. 3. Earnings per share The calculation of basic earnings per share is based on the unaudited profit attributable to shareholders for the six months ended 30 June 2004 of approximately RMB24,102,000 (2003: RMB 15,464,000) and on the weighted average of 561,000,000 shares in issue during the six months ended 30 June 2004 (2003: 561,000,000 shares) 4. Dividend The Board does not recommend the payment of any interim dividend in respect of the six months ended 30 June 2004(2003:Nil) |